Latest news articles

Added 4 days ago Drug news

EU approves Cabometyx to treat intermediate- or poor- risk advanced renal cell carcinoma.- Ipsen + Exelixis Inc.

Ipsen has announced that the European Commission (EC) has approved Cabometyx (cabozantinib) 20, 40, 60 mg for the first-line treatment...

Added 1 month ago Drug news

Rocapuldencel-T + sunitinib combination fails Phase III ADAPT trial to treat renal cell carcinoma.-Argos Therapeutics.

Argos Therapeutics, Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis precision...

Added 1 month ago Drug news

FDA approves combination Opdivo + Yervoy to treat intermediate- and poor-risk advanced renal cell carcinoma.- BMS.

Bristol-Myers Squibb Company has announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was...

Search all news articles for Cancer of kidney and renal pelvis
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Prostate Cancer

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

+ 5 more

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Load more

Guidelines

Guidelines on Renal Cell Carcinoma

The European Association of Urology (EAU) Renal Cell Cancer (RCC) Guidelines Panel has compiled these clinical guidelines to provide urologists with evidence-based information and recommendations for the management of renal cell cancer.

Added 2 years ago

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women, respectively, thus representing the 7th most common cancer in men and the 10th most common cancer in women.

Added 3 years ago

Search all guidelines for Cancer of kidney and renal pelvis
 

Journal articles

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.

Background: Tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 tyrosine kinases. This open-label, crossover clinical study (AV-951-09-902) provided access to tivozanib for patients...

Added 2 months ago

Tivozanib: a new treatment option for renal cell carcinoma.

Tivozanib is a tyrosine kinase inhibitor that targets all vascular endothelial growth factor receptors (VEGFRs), causing inhibition of angiogenesis. It has recently been approved by the European Medicines Agency (EMA)...

Added 2 months ago

Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials.

High-risk, localized renal cancer is associated with recurrence rates of up to 75% at 10 years. The outcomes of patients at this disease stage depend on optimal patient stratification, surgical management and systemic therapy selection.

Added 4 months ago

Search all journal articles for Cancer of kidney and renal pelvis
 

Clinical trials

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma [IMmotion151]

This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC)...

Added 5 months ago

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.

Added 4 years ago

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003...

Added 6 months ago

Search all clinical trials for Cancer of kidney and renal pelvis
 
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.